Paper Details

  1. Home
  2. Paper Details

Hepatitis C virus therapy: No one will be left behind.

Author: BourlièreMarc, PietriOlivia

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Oral direct-acting antiviral agents (DAAs) have dramatically improved the treatment landscape for hepatitis C, achieving cure rates over 95% with shorter treatment durations and excellent safety profiles. The introduction of pangenotypic fixed-dose combinations (FDCs) in 2017 further simplified treatment and increased access for nearly all hepatitis C patients.
Paper Details　
Original Abstract of the Article :
The advent of oral direct-acting antiviral agents (DAAs) has dramatically improved the hepatitis C treatment landscape in the last 4 years, providing cure rates over 95% with shorter duration of treatment and a very good safety profile. This gave access to treatment to almost all Hepatitis C virus (...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ijantimicag.2018.12.010

データ提供：米国国立医学図書館（NLM）

A New Dawn for Hepatitis C Treatment: Leaving No One Behind

Hepatitis C, a viral infection that affects the liver, has been a formidable foe in the desert of medical research. This review article explores the transformative impact of direct-acting antiviral agents (DAAs) on hepatitis C treatment, highlighting their remarkable efficacy and safety profile. The advent of these new drugs has revolutionized the treatment landscape, offering hope for a cure to millions.

DAAs: A Game-Changer in the Fight Against Hepatitis C

DAAs have emerged as a powerful weapon in the fight against hepatitis C. They offer cure rates exceeding 95%, shorter treatment durations, and a favorable safety profile. The development of pangenotypic fixed-dose combinations (FDCs) has further advanced the treatment landscape, making it possible to treat patients without the need for HCV genotyping or fibrosis assessment. This progress represents a significant victory in the ongoing battle against this persistent infection.

A Brighter Future for Hepatitis C Patients: A Desert Oasis of Hope

The advent of DAAs offers a ray of hope for individuals living with hepatitis C. These new drugs have dramatically improved treatment outcomes, providing a path toward a cure for many. The journey towards eradicating hepatitis C continues, but the development of DAAs is a testament to the remarkable progress we've made in combating this infectious disease. With continued research and innovation, we can create a healthier future for all those affected by hepatitis C.

Dr.Camel's Conclusion

The development of DAAs has revolutionized hepatitis C treatment, offering cure rates exceeding 95% and paving the way for a healthier future for millions. This remarkable progress is a testament to the power of scientific innovation and a beacon of hope for those battling this challenging infection. As we journey through the desert of medical research, DAAs represent a significant milestone in our fight against hepatitis C.
Date :
  1. Date Completed 2019-09-02
  2. Date Revised 2019-09-02
Further Info :

Pubmed ID

30605721

DOI: Digital Object Identifier

10.1016/j.ijantimicag.2018.12.010

Related Literature

Article Analysis
・Side Effects of daclatasvir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.